(Q33417191)

English

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

26 July 2017

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

non-Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

object named as

Paul A Hamlin

8

0 references

author name string

Nizar M Tannir

1

1 reference

Europe PubMed Central

26 July 2017

Andres Forero-Torres

2

1 reference

Europe PubMed Central

26 July 2017

Radhakrishnan Ramchandren

3

1 reference

Europe PubMed Central

26 July 2017

Sumanta K Pal

4

1 reference

Europe PubMed Central

26 July 2017

Stephen M Ansell

5

1 reference

Europe PubMed Central

26 July 2017

Jeffrey R Infante

6

1 reference

Europe PubMed Central

26 July 2017

Sven de Vos

7

1 reference

Europe PubMed Central

26 July 2017

Stella K Kim

9

1 reference

Europe PubMed Central

26 July 2017

Nancy C Whiting

10

1 reference

Europe PubMed Central

26 July 2017

Elaina M Gartner

11

1 reference

Europe PubMed Central

26 July 2017

Baiteng Zhao

12

1 reference

Europe PubMed Central

26 July 2017

John A Thompson

13

1 reference

Europe PubMed Central

26 July 2017

publication date

22 August 2014

1 reference

Europe PubMed Central

26 July 2017

Investigational New Drugs

1 reference

Europe PubMed Central

26 July 2017

32

1 reference

Europe PubMed Central

26 July 2017

6

1 reference

Europe PubMed Central

26 July 2017

1246-1257

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1007/s10637-014-0151-0

0 references

Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Comparative molecular modelling of the Fas-ligand and other members of the TNF family

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

CD70 as a therapeutic target in human malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

CD27: marker and mediator of T-cell activation?

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

CD27 and CD70 in T cell and B cell activation

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

CD70+ non-Hodgkin lymphoma B cells induce Foxp3 expression and regulatory function in intratumoral CD4+CD25 T cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Identification of CD70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, real-time RT-PCR and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Aberrant expression and reverse signalling of CD70 on malignant B cells

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Autoimmune thrombocytopenia in non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

The CD27 and CD70 costimulatory pathway inhibits effector function of T helper 17 cells and attenuates associated autoimmunity

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-014-0151-0

21 January 2018

Preclinical characterization of SGN-70, a humanized antibody directed against CD70

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The pharmacologic basis for antibody-auristatin conjugate activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Control of lymphocyte function through CD27–CD70 interactions

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phenotype and function of human B cells expressing CD70 (CD27 ligand)

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cloning of CD70 and its identification as the ligand for CD27

1 reference

https://pubmed.ncbi.nlm.nih.gov/25142258

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-014-0151-0

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33417191&oldid=1536314103"